

1 **Real-time visualization and quantification of human Cytomegalovirus**  
2 **replication in living cells using the ANCHOR DNA labeling technology.**

3 Bernard Mariamé<sup>1,2</sup>, Sandrine Kappler-Gratias<sup>2,5</sup>, Martin Kappler<sup>3</sup>, Stéphanie Balor<sup>1,4</sup>, Franck  
4 Gallardo<sup>2,5</sup># and Kerstin Bystricky<sup>1,2</sup>#

5 <sup>1</sup> Laboratoire de Biologie Moléculaire Eucaryote, Centre de Biologie Intégrative, CNRS, Paul  
6 Sabatier University of Toulouse; F- 31062 Toulouse, France.

7 <sup>2</sup> Institute for Advanced Life Science Technology ; ITAV USR3505; F-31000 Toulouse,  
8 France

9 <sup>3</sup> statalpha ; F-31450 Baziège, France

10 <sup>4</sup> Plateforme de Microscopie électronique intégrative (METi) ; FRBT CNRS FR3451; F-  
11 31062 Toulouse, France

12 <sup>5</sup> NeoVirTech SAS ; F-31000 Toulouse, France

13 # Address correspondence to: [fgallardo@neovirtech.com](mailto:fgallardo@neovirtech.com) ; [kerstin.bystricky@ibcg.biotoul.fr](mailto:kerstin.bystricky@ibcg.biotoul.fr)

14 Running title : “Live cell imaging of fluorescent ANCHOR-HCMV replication.”

15 Keywords : HCMV, fluorescent virus, replication, live imaging, anti-viral screening.

16 **ABSTRACT (209 words)**

17 Human cytomegalovirus (HCMV) induces latent life-long infections in all human  
18 populations. Depending on geographic area and socio-economic conditions between 30 to  
19 nearly 100% of individuals are affected. The biology of this virus is difficult to explore due to  
20 its extreme sophistication and the lack of pertinent animal model. Here we present the first  
21 application of the ANCHOR DNA labeling system to a herpes virus, allowing real time  
22 imaging and direct monitoring of HCMV infection and replication in human living cells. The  
23 ANCHOR system is composed of a protein (OR) which specifically binds to a short, non-

24 repetitive DNA target sequence (ANCH) and spreads onto neighboring sequences due to  
25 protein oligomerization. If OR protein is fused to GFP, this accumulation results in a site  
26 specific fluorescent focus. We have created a recombinant ANCHOR- HCMV harboring an  
27 ANCH target sequence and the gene encoding the cognate OR-GFP fusion protein. Infection  
28 of permissive cells with ANCHOR-HCMV enables visualization of the nearly complete viral  
29 cycle until cell fragmentation and death. Quantitative analysis of infection kinetics and of  
30 viral DNA replication revealed cell-type specific behavior of HCMV and sensitivity to  
31 inhibitors. Our results show that the ANCHOR technology is a very efficient tool for the  
32 study of complex DNA viruses and new highly promising biotechnology applications.

### 33 **IMPORTANCE** (147 words)

34 The ANCHOR technology is to date the most powerful tool to follow and quantify the  
35 replication of HCMV in living cells and to gain new insights into its biology. This technology  
36 is applicable to virtually any DNA virus or virus presenting a dsDNA phase, paving the way  
37 to infection imaging in various cell lines or even in animal models and opening fascinating  
38 fundamental and applied prospects. Associated to high content automated microscopy, this  
39 technology permitted rapid, robust and precise determination of Ganciclovir IC50 and IC90  
40 on HCMV replication, with minimal hands-on investment. To search for new antiviral  
41 activities, the experiment is easy to up-grade towards efficient and cost-effective screening of  
42 large chemical libraries. The simple infection of permissive cells with ANCHOR-viruses in  
43 the presence of a compound of interest may even provide a first estimation about the stage of  
44 the viral cycle this molecule is acting upon.

### 45 **INTRODUCTION**

46 Human cytomegalovirus (HCMV), also called Human Herpesvirus 5 (HHV5), belongs to the  
47 *β-herpesviridae* family and, as all herpesviruses (HV), is able to establish life-long latency in

48 infected individuals (1). HCMV is the largest HHV with a double stranded DNA genome of  
49 about 240kb. It is usually transmitted through body fluids such as saliva, urine or breast milk  
50 but also through sexual contacts (2). Primary infection is generally benign or silent in healthy  
51 individuals but may be much more serious and even life threatening in immuno-compromised  
52 patients, especially those having received hematopoietic cells or solid organ transplants, or  
53 AIDS patients. The virus is also able to cross the placental barrier and primary HCMV  
54 infection during pregnancy, especially during the first quarter, is the leading cause of birth  
55 defects, with an estimation of one million HCMV congenital infections worldwide per year  
56 (3, 4). Among these infections, possibly up to 25% of newborns will keep sensorineural and  
57 intellectual deficits. *In vivo* infection is poorly understood but most likely initiates in a  
58 mucosal tissue and then spreads through blood monocytes which disseminate the virus in  
59 numerous susceptible sites. HCMV binds to heparan sulfate proteoglycan (5) and to numerous  
60 cell membrane structures among which CD13 (6), annexin II (7), DC-SIGN (8), EGFR (9)  
61 and PDGFR- $\alpha$  (10) are candidate receptors. This may in part explain the remarkably broad  
62 cell tropism of this virus which is able to infect and replicate in numerous cell types including  
63 epithelial, dendritic, fibroblastic, endothelial or smooth muscle cells (11) and to establish  
64 latency in CD34+ hematopoietic progenitor cells (12). Long lasting efforts have allowed  
65 partial deciphering of the biology of this highly sophisticated virus but much remains to be  
66 done with regard to *in vivo* infection kinetics. Techniques to track real time infections in live  
67 cells have been developed for RNA viruses (13, 14, 15) and also for Herpes viruses (16, 17,  
68 18). However, up to now, fluorescent tracking of HVs relied on simple GFP expression or on  
69 fusion of the GFP gene with a structural viral gene. These engineered viruses have greatly  
70 contributed to some pioneering work but did not provide quantitative information about  
71 replication kinetics of the viral genome. Therefore, to gain a better understanding of the  
72 fundamental biology of HVs, we have introduced a new technology enabling real time follow-

73 up and counting of viral genomes during infection in live cells and also possibly in live  
74 animal models. In this paper, we present the use of the patented ANCHOR DNA labeling  
75 technology (19) for tracking of HCMV in living cells. ANCHOR is a bipartite system derived  
76 from a bacterial parABS chromosome segregation machinery. Under its natural form in  
77 bacteria, the parABS system consists in a short non repetitive target DNA sequence  
78 containing a limited number of nucleation parS sites to which the parB proteins bind and then  
79 spread onto adjacent DNA through a mechanism of protein-protein interaction. The third  
80 component of the system is an ATPase involved in the last steps of bacterial chromosomes or  
81 plasmids segregation. Under its engineered form, called ANCHOR, the OR protein (ParB)  
82 specifically binds to the cognate, shortened, ANCH sequence, which comprises palindromic  
83 parS nucleation sites (20, 21). If the OR protein is fused to a fluorescent protein (FP), its  
84 accumulation on the ANCH target sequence and spreading over neighboring sequences result  
85 in the formation of an easily detectable fluorescent focus, thereby identifying the position of  
86 the ANCH tagged DNA locus (Fig.1a). Different ANCHOR systems (1 to 4, derived from  
87 various bacteria) have been used successfully to analyze motion of single genomic loci and  
88 DNA double strand break processing in living yeast (22) and chromatin dynamics during  
89 transcription in human cells (23). These ANCHOR systems were shown not to perturb  
90 chromatin structure and function despite the presence of up to 500 OR proteins on and  
91 around the ANCH sequence (23). Here, we have created HCMV genomes containing the  
92 ANCH2 target sequence (HCMV- ANCH2) or both the ANCH3 target sequence and the gene  
93 encoding the corresponding OR3-GFP protein (HCMV-ANCHOR3). In the latter case, OR3-  
94 GFP proteins (which do not present any known intracellular localization sequence) freely  
95 diffuse in the cell and rapidly associate with the ANCH3 sequence, rendering the HCMV  
96 DNA fluorescent and detectable by microscopy as well defined spots over a uniform  
97 background of OR-GFP proteins. Thanks to these engineered virions, we were able to

98 visualize early infection and initial duplication of the incoming genomes, viral DNA  
99 amplification, replication and cell death in real time and in live cells. All these steps were  
100 simply observed by microscopic examination, with no additional manipulation and without  
101 fixation, extraction or reagents of any kind, emphasizing the ease in use, the power and  
102 potential of this technology. Furthermore, analyzing the effect of Ganciclovir on ANCHOR-  
103 HCMV infection illustrates the remarkable potential of this technology for time and cost-  
104 effective screening of compound libraries in the search of new antiviral molecules. Its  
105 suitability for labeling any DNA virus (and possibly any virus presenting a dsDNA phase)  
106 offers unprecedented opportunities for new biotechnology applications.

## 107 **MATERIAL AND METHODS**

### 108 **Viruses and Bacterial Artificial Chromosomes (BAC).**

109 The TB40/E HCMV strain was obtained from a throat wash of a bone marrow transplant  
110 recipient patient (24) and its genome was cloned as a BAC in E.coli by replacing the non-  
111 essential US2 to US7 viral genes with the BAC vector pEB1097 (24, 25). This construct was  
112 later modified by inserting the GFP gene under the control of the murine CMV Immediate  
113 Early promoter (mCMV-MIEP) in the vector sequence, providing the TB40-GFP BAC (E.  
114 Borst, personal communication). This BAC has been maintained, amplified and mutated in  
115 DH10B bacteria grown in LB broth supplemented with the appropriate antibiotics. For the  
116 production of viruses from BACs, BAC DNA was first purified from bacteria using the  
117 PureLink HiPure Plasmid DNA Purification Kit (InVitroGen) or the NucleoBond XTRA  
118 BAC Kit (Macherey Nagel) according to manufacturer's specific instructions. DNA was then  
119 transfected in MRC5 permissive human lung fibroblasts with X-tremeGENE<sup>TM</sup> HP or X-  
120 tremeGENE<sup>TM</sup> 9 transfection Reagents (Roche) following provided recommendations. When  
121 cytopathic effects reached nearly 100% of the cells, the content of the flask was harvested,

122 centrifuged for 10 minutes at 2000RPM to remove cell debris and the supernatant was  
123 centrifuged at 25000 RPM (106000g) for 45 minutes at 16°C in a SW32Ti rotor (Beckman)  
124 on a 20% sucrose cushion. Alternatively, after the first centrifugation, supernatant could also  
125 be centrifuged at 20000 RPM (48500g) for 90 minutes at 16°C in a JA25.50 fixed angle rotor  
126 on a 20% sucrose cushion with similar virus yield. With both techniques, easily visible pellets  
127 were obtained under the cushion, resuspended in DMEM-20%FCS, aliquoted in vials and  
128 frozen at -80°C. The ANCHOR modified HCMV BACs were derived from the TB40-GFP  
129 BAC (a kind gift of Drs. E. Borst and M. Messerle). As a first proof of concept, the TB40-  
130 GFP BAC was initially modified by introducing an ANCH2 target sequence instead of the  
131 mCMV-MIEP-GFP gene. Briefly, the ANCH2 sequence and a kanamycine resistance gene  
132 were amplified respectively from the pUC18-ANCH2 (22) and the pORI6K-5FRT (a kind gift  
133 of Dr. M. Messerle) plasmids using PrimeStar Max 2X (TAKARA) according to  
134 manufacturer's recommendations. The fragments were then purified, phosphorylated, ligated  
135 and the ligation product was used as template for a second amplification between new primers  
136 selecting the required product of ligation and introducing at both extremities 50bp homology  
137 sequences (H1 and H2) necessary for the final recombination of this product in the TB40-GFP  
138 BAC. This H1-Kana<sup>R</sup>-ANCH2-H2 cassette (Fig.2) has been cloned between the PvuII sites of  
139 the pGEM-7Zf(+) vector (PROMEGA) using NdeI or ApaI linkers (pGΔANCH2-kana).  
140 DH10B bacteria containing the TB40-GFP BAC were first transformed with the pKD46  
141 vector encoding the arabinose inducible phage Red  $\alpha$ ,  $\beta$  and  $\gamma$  recombinases and then, with  
142 the purified H1-Kana<sup>R</sup>-ANCH2-H2 cassette. Recombinant clones were obtained, analyzed by  
143 BamHI digestion profile and the clone TB40-ANCH2-Kana was finally verified by  
144 sequencing (Fig.2). This BAC was amplified, purified and transfected into MRC5 human  
145 fibroblasts. Complete cytopathic effects were observed 4 weeks later and at this time, the  
146 content of the flask was harvested and viruses purified as described above. We next created

147 the TB40-ANCHOR3 BAC by replacing the mCMV-MIEP-GFP sequence of the TB40-GFP  
148 BAC with a cassette containing the ANCH3 target sequence, a chimerical gene encoding the  
149 OR3 protein fused to GFP under the control of a SV40 promoter and a kanamycine resistance  
150 gene as a selection marker. This cassette was derived from the previously obtained  
151 pG $\Delta$ ANCH2-kana plasmid of which the ANCH2 sequence had been removed by PmlI  
152 digestion and replaced with an ANCH3 sequence, providing construct pG $\Delta$ ANCH3-kana. The  
153 OR3 gene had already be cloned in the peGFPc1 vector (Clontech) and a SV40 promoter was  
154 inserted directly upstream of the GFP-OR3 gene providing the pSVGO3 plasmid. The  
155 pSV40GFP-OR3 cassette was excised from the pSVGO3 plasmid and inserted in the  
156 MluI/PvuII sites of the pG $\Delta$ ANCH3-kana plasmid, creating the  
157 pG7 $\Delta$ KanaSVOR3GFPANCH3 vector. Finally, the cassette of interest with the following  
158 structure H1-kana-OR3GFP-pSV40-ANCH3-H2 was excised by NdeI digestion, agarose gel  
159 purified and used for recombination in TB40-GFP containing DH10B bacteria. Obtained  
160 clones were screened by BamHI, EcoRI or HindIII restriction profiles and one of them,  
161 showing the expected modification, was named TB40-ANCHOR3 and further confirmed by  
162 PCR and DNA sequencing (Fig.2). This clone was then amplified, purified and transfected  
163 into MRC5 human fibroblasts. Complete cytopathic effects were observed 5 weeks later. At  
164 this time, viruses were purified and stored as described above. To create a pure ANCHOR-  
165 modified viral stock from this first production, 10<sup>4</sup> MRC5 cells plated in 96 well plates  
166 (imaging grade, Corning Cell Bind) were infected with 0.5 virus per well. Albeit more than  
167 half of the wells did not display infection, one isolated green fluorescent plaque could be  
168 recovered and used to infect 10<sup>4</sup> fresh MRC5 cells. After cell lysis, the culture medium was  
169 transferred to two T175 flasks of MRC5 cells which were incubated until cytopathic effects  
170 were estimated maximum (12 weeks from plaque picking). At this time, the content of the

171 flasks was harvested and viruses purified as described, providing a stock of  $8.10^8$  TB40-  
172 ANCHOR3 viruses.

173 **Plaque forming assay.**

174 For quantification by plaque forming assay,  $10^5$  MRC5 cells/well were plated in 24-well  
175 plates. The day after, culture medium is removed and cells are infected with various dilutions  
176 of the virus stock to be titrated. After two or sixteen hours contact, virus dilutions were  
177 removed and replaced with fresh supplemented culture medium containing 0.5% low-melting-  
178 point agarose and plaques were allowed to develop until they become visible. At this time,  
179 cells were fixed by addition of 1mL of 2% formaldehyde and plaques counted after staining  
180 with 0.02% methylene blue (26).

181 **Replication rate assay.**

182 To measure replication rates,  $10^5$  MRC5 cells/well were seeded in two 24-well plates and  
183 infected with the TB40-GFP or the TB40-ANCHOR3 viruses at an MOI of 0.2. After 3 hours  
184 of contact, supernatants were removed, replaced with fresh medium and plates were incubated  
185 at 37°C under 5% CO<sub>2</sub>. One of the plates with a glass bottom was used to determine the  
186 number of cells and of fluorescent infected cells at each time point. Supernatants and cells  
187 were separately collected from duplicate wells of the second plate 1, 2, 4, 6, 8 or 10 days post  
188 infection. Supernatants were directly extracted with phenol and chloroform-isoamyl alcohol  
189 mixture and ethanol precipitated in the presence of HCMV-free carrier DNA. After  
190 centrifugation, DNA pellets were resuspended in 100µL sterile TE and conserved at 4°C.  
191 DNAs from the infected cells were purified using the NucleoSpin DNA RapidLyse kit  
192 (Macherey Nagel, ref. 740100.50) according to manufacturer's instructions and eluted in a  
193 final volume of 200µL. Viral DNA quantification was performed in triplicate by qPCR using  
194 a LightCycler<sup>R</sup>480SYBR Green I Master kit (Roche, 04707516001). The cloned UL79 gene  
195 was chosen as the reference and the fragment flanked by primers UL79.1F



196 (CAGATTAGCGAGAAGATGTCTG) and UL79.1R (CAGGTTGTTTCATGGTTTCGC) was  
197 amplified with a PCR efficiency ranging between 1.999 and 2.007.

### 198 **Cells, Culture, and Media**

199 Human primary fibroblasts MRC5 (CCL-171) and human retinal pigmented epithelium cells  
200 ARPE-19 (CRL-2302), were obtained from ATCC and were grown in DMEM without phenol  
201 red (Gibco) supplemented with 10% FBS, 1x Penicilline-Streptomycine, 1 mM sodium  
202 pyruvate and 1x Glutamax (Gibco). Human umbilical vein endothelial cells (HUVEC, a kind  
203 gift of Dr. Melinda Benard) were grown in EGM-2 medium including supplement  
204 (PromoCell).

### 205 **Chromatin immunoprecipitation**

206 ChIP assays were performed as described by Metivier *et al.* (27) with minor modifications.  
207 MRC5 cells infected at MOI 0.5 with TB40-GFP or TB40-ANCHOR3 viruses were treated  
208 72h post-infection (pi.) with 1.5% formaldehyde for 10 min. Cross-link was stopped with 1M  
209 Glycin for 30 seconds and cells were washed with cold PBS. After nucleus preparation with  
210 Buffer NCPI (EDTA 10mM, EGTA 0.5mM, Hepes 10mM and TritonX-100 0.2%) and buffer  
211 NCPII (EDTA 1mM, EGTA 0.5mM, Hepes 10mM and NaCl 200mM) cell lysis was  
212 performed (10 mM EDTA, 50 mM Tris-HCl [pH 8.0], 1% SDS, 1x protease inhibitor cocktail  
213 [Roche Biochemicals, Mannheim, Germany]). Subsequently chromatin was either digested 3h  
214 at 37°C with DrdI and ScaI restriction enzymes and sonicated three times 10 seconds or not  
215 treated at all. Immunoprecipitations were performed overnight in the presence or not of 2 µg  
216 of selected antibody. Complexes were recovered by a 2 hr incubation with protein A  
217 Sepharose CL4B saturated with salmon sperm DNA. Beads were sequentially washed in  
218 buffer I (2 mM EDTA, 20 mM Tris-HCl, pH8.1, and 150 mM NaCl), buffer II (2 mM EDTA,  
219 20 mM Tris-HCl, pH 8.1, 0.1% SDS, 1% Triton X-100, and 500 mM NaCl), buffer III (1 mM  
220 EDTA, 10 mM Tris-HCl, pH 8.1, 1% Nonidet P-40, 1% deoxycholate, and 250 mM LiCl),

221 and three times with Tris-EDTA buffer. Washed resin was resuspended in elution buffer (1%  
222 SDS, 0.1 M NaHCO<sub>3</sub>) with 30-min incubation and the cross-link was reversed at 65°C  
223 overnight. DNA was purified with QIAquick columns (Qiagen, France). After  
224 immunoprecipitation with anti-GFP antibodies, PCR were performed with the following  
225 oligonucleotides: ANCH3-P7 (S) and (AS) (contact@NeoVirTech.com); CMV-P3 (S)  
226 CCGTACTTCGTCTGTCGTTT and (AS) TGTGTCTGTTTGATTCCCCG; CMV-P1 (S)  
227 ACGGCAAGTCCATAATCACC and (AS) GACCGATCCCACCAATTCTC ; GFP-P1 (S)  
228 ACGTTGTGGCTGTTGTAGTT and (AS) GACTTCTTCAAGTCCGCCAT.

### 229 **High-Content Imaging**

230 MRC5 cells are seeded at 10<sup>4</sup> cells/well in Corning *Cellbind* black glass-bottom 96-well  
231 plates and infected twenty-four hours post-seeding with ANCHOR engineered HCMV at  
232 various MOI. For analysis, cells were directly stained with Hoechst 33342 (1µg/ml) and  
233 imaged using a Thermo Scientific Cellomics Arrayscan Vti microscope. Compartmental  
234 analysis was used to detect and quantify infection rate ie the number of GFP positive cells vs  
235 total number of cells. For spot counting and measure of viral DNA accumulation in the nuclei  
236 of infected cells, we used spot detector plugin for ImageJ with the following settings: spot  
237 radius 2, cutoff 0, percentile 7. Measurements were done for 1000 cells and average +/-SD  
238 were displayed from triplicates. Full analysis protocols for Arrayscan imaging are available  
239 upon request.

### 240 **IC50 calculation**

241 In order to determine the IC50, a nonlinear regression was applied using the natural logarithm  
242 of the viral DNA content as dependent variable, the natural logarithm of the concentration as  
243 continuous predictor and the plate as covariate according to the following model :

$$\ln(\text{viral DNA content [FU]}) = \frac{\mu \pm \gamma \cdot \text{Plate}}{1 + \exp(\alpha + \beta \cdot \ln(\text{Concentration } [\mu\text{M}]))}$$

244 where  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\mu$  are the parameters of a non-linear regression.

245 The nonlinear regression was realized using R and the results are presented using the package  
246 ggplot2 (28).

247

## 248 **Fluorescence imaging**

249 Live microscopy was performed using a Zeiss Axio Observer Z1, Apotome 2 wide-field  
250 fluorescence microscope. Conditions of acquisition are detailed in figure legends.

251

## 252 **Immunofluorescence**

253 For immunofluorescence analysis, TB40-ANCHOR3 infected MRC5 cells were fixed in PBS  
254 containing 3.6% formaldehyde at different times pi., washed and then permeabilized in 10mM  
255 Hepes containing 0.5% Triton X-100 and 1% BSA. After washing, the cells were incubated  
256 for 1 hour at room temperature with the first antibodies diluted according to manufacturer's  
257 recommendations, washed again and further incubated for 45 minutes in the appropriately  
258 diluted secondary antibodies. Cells were washed again and stained with Hoechst 33342 at the  
259 final concentration of 1 $\mu$ g/mL before fluorescence microscopic examination. For direct  
260 immunofluorescence of viral particles, diluted viruses were spotted on poly-L-Lysine pre-  
261 coated Ibidi glass bottom 35 mm dishes. Following a ten minute incubation,  
262 immunofluorescence was performed as described, with slight modifications. Due to the small  
263 size of viral particles, incubations were shortened to 30 min for primary and to 15 min for  
264 secondary antibodies.

## 265 **Correlative light and electron microscopy**

266 MRC5 cells were grown on MatTek dishes with a finder grid (29) and infected with the  
267 TB40-ANCHOR3 virus at a MOI of 1. Four days post-infection, cells were fixed with 0.05%  
268 glutaraldehyde (GA) and 4% paraformaldehyde (PFA) for 30 min at room temperature. Image

269 acquisition and analysis was performed on an Olympus IX81 epifluorescence microscope  
270 equipped with a x100 objective lens (UPlan SApo 1.4 oil), a SpectraX illumination system  
271 (Lumencore©) and a CMOS camera (Hamamatsu© ORCA-Flash 4.0). Stacks of 51 images  
272 each, with a step size of 0.1  $\mu\text{m}$ , were taken. Cells were then fixed overnight with 2.5% GA  
273 in cacodylate buffer pH 7.2 and post fixed in 1% osmium in distilled water for 30 min. The  
274 samples were then rinsed in water and dehydrated in an ethanol series and flat embedded in  
275 Epon. Sections were cut on a Leica Ultracut microtome and ultra-thin sections were mounted  
276 on Formvar-coated slot copper grids. Finally, thin sections were stained with 1% uranyl  
277 acetate and lead citrate and examined with a transmission electron microscope (Jeol JEM-  
278 1400) at 80 kV. Images were acquired using a digital camera (Gatan Orius) at 200 and 2500X  
279 magnification. Alignments were performed as published (30).

## 280 **RESULTS**

### 281 **Construction of the ANCHOR-HCMV BACs**

282 Two ANCHOR-modified HCMV-BACs were derived from the TB40-GFP BAC (a kind gift  
283 of Drs. E. Borst and M. Messerle). The first one, TB40-ANCH2-Kana, was obtained by  
284 replacing the mCMV-MIEP-GFP gene of the TB40-GFP with a single ANCH2 target  
285 sequence (together with a selection kanamycine resistance gene). The TB40-ANCHOR3 BAC  
286 was constructed in a similar way but replacing the mCMV-MIEP-GFP sequence with a  
287 cassette containing the ANCH3 target sequence, a chimerical OR3-GFP gene driven by an  
288 SV40 promoter and a kanamycine resistance gene (Fig.2, see Material and Methods).  
289 Contrary to the TB40-ANCH2-Kana virus which requires separate transfection of an  
290 expression vector for its corresponding OR2 protein, the TB40-ANCHOR3 is autonomous in  
291 that it contains the ANCH3 target sequence and the gene encoding its cognate OR3 protein  
292 (fused to the GFP gene).

293 **Viruses derived from the TB40-ANCHOR-HCMV BACs are infectious.**

294 Transfections of the purified TB40-ANCHOR BACs in MRC5 fibroblasts were poorly  
295 efficient, likely due to their very large size and to low transfection efficacy of the cells. Only  
296 sparse foci of modified cells were observed 10 days post transfection. However, nearly 100%  
297 cytopathic effects were reached 4 to 5 weeks after transfection, indicating that the rare cells  
298 which were transfected with the TB40-ANCHOR BACs produced viruses that were fully  
299 infectious. In order to confirm infectivity and to assess whether TB40-ANCHOR3 viruses had  
300 conserved the epithelial and endothelial tropism of the original TB40 HCMV strain, TB40-  
301 ANCHOR3 viruses were used to infect new MRC5, HUVEC or ARPE-19 cells, respectively  
302 fibroblasts, endothelial and retinal epithelial cells. The three cell types became readily  
303 infected with appearance of fluorescence and fluorescent spots several hours pi, confirming  
304 infectivity of the ANCHOR engineered viruses and the preservation of the original cellular  
305 tropism (Fig. 1b, Supplementary Fig.S1). However, infection efficacy and kinetics were  
306 clearly cell type dependent as the number of infected cells in the presence of the same amount  
307 of virus, varied largely from one cell type to the other. As a first estimate of its replication  
308 capacity, the TB40-ANCHOR3 viral stock was titrated using two different techniques: a  
309 fluorescence assay and a classical plaque forming assay. MRC5 cells were infected with  
310 different dilutions of the viral stock for 2 or 18 hours, washed and incubated as described. The  
311 plate of the fluorescent assay was analyzed with an automated ArrayScan microscope 60h pi.,  
312 while the plate with the plaque forming assay was maintained at 37°C for 12 days and then  
313 fixed, stained and analyzed. As shown in Table 1, very similar results were obtained with both  
314 techniques indicating that the viruses infecting the cells render them fluorescent and are also  
315 able to induce a complete lytic cycle. Interestingly, the contact time between cells and viruses  
316 matters as the longer infection times systematically result in higher titers than the shorter  
317 ones, whichever the technique is used. However, even if both techniques are reliable, the

318 fluorescent one is clearly less labor-intensive, more rapid, robust and reproducible and was  
319 hence adopted for all further titrations

320 **ANCHOR modification does not interfere with virus replication rate.**

321 To quantify more precisely data about their replication kinetics, we infected MRC5 cells with  
322 TB40-GFP and TB40-ANCHOR3 viruses at an MOI of 0.2, and measured the number of viral  
323 genomes present in cells and in their supernatants until 10 days post infection (Table 2).  
324 Values measured in supernatants were compared with those published for the TB40-BAC4  
325 (31) and are presented in Fig.3. Both in supernatants and in cells, the number of TB40-  
326 ANCHOR3 genomes is larger than the one determined for TB40-GFP, suggesting that TB40-  
327 ANCHOR3 replicates more efficiently. TB40-GFP and the TB40-BAC4 strains produce  
328 similar number of genomes in supernatants. These results show that the presence of the  
329 ANCHOR sequences in the viral genome does not impair its replication nor induces important  
330 functional deletion.

331

332 **Viruses derived from the TB40-ANCHOR-HCMV BAC are fluorescent and mature.**

333 TB40-ANCHOR3 viruses from the purified viral stock were immobilized on poly-lysine  
334 treated glass slides and stained with Hoechst and anti-pp28 or anti-gB antibodies. As shown in  
335 Fig.4, Hoechst, GFP, anti-pp28 and anti-gB signals perfectly superimpose suggesting that  
336 these viral particles are mature, tegumented, enveloped and contain DNA and OR3- GFP  
337 proteins.

338 **OR-GFP proteins effectively bind to ANCH sequences in ANCHOR-HCMV infected**  
339 **cells.**

340 Binding of OR proteins to cognate engineered ANCH target sequences was previously  
341 demonstrated in pro- and eukaryotic systems (22). We confirmed that the same held true in  
342 cells infected with our HCMV-ANCHOR. For this purpose, chromatin immunoprecipitation

343 (ChIP) experiments were performed on cells infected with TB40-GFP or TB40-ANCHOR3  
344 viruses using antibodies against GFP. As shown in Fig. 5a, DNA immunoprecipitated from  
345 TB40-ANCHOR3 infected cells is strongly enriched in ANCH3 sequences, confirming OR3-  
346 GFP proteins bind to the ANCH3 target sequence. Enrichment in the adjacent GFP sequence  
347 suggests spreading of OR3-GFP onto neighboring DNA. No significant enrichment of more  
348 distant sequences was observed. Similarly, no significant enrichment was observed in DNA  
349 from cells infected with the TB40-GFP virus immunoprecipitated with anti-GFP antibodies.

350 **In infected cells, fluorescent spots result from OR-FP binding to ANCH-HCMV**  
351 **genomes.**

352 To determine the nature of the observed spots (Fig.1b, Supplementary Fig.1), we took  
353 advantage of our TB40-ANCH2-Kana virus which contains a single ANCH2 sequence but no  
354 OR-FP gene. When MRC5 cells were solely infected with the TB40-ANCH2-Kana viruses,  
355 no fluorescence was observed (results not shown). Transfection of an expression vector for  
356 OR2-GFP proteins in uninfected MRC5 cells resulted in uniform fluorescence in all cell  
357 compartments while infection of OR2-GFP transfected cells with the TB40-ANCH2-Kana  
358 virus resulted in the appearance of numerous bright spots 72 hours post-infection (Fig.5b). As  
359 a control, MRC5 cells which had been transfected with an expression vector for OR3-mcherry  
360 were infected with the TB40-GFP virus: as shown in Fig5c., 72hours pi., doubly fluorescent  
361 (red and green) cells did not display any spot similar to those observed in Fig. 5b or S1  
362 despite the fact that a nuclear structure resembling a replication compartment is clearly visible  
363 (Fig.5c). These two experiments together demonstrate, on one hand, that OR-FP proteins or  
364 viral genomes alone do not form any spot and, on the other hand that OR-FP proteins do not  
365 form non-specific spots on HCMV genomes. Therefore, taken together with the ChIP  
366 experiments, these results demonstrate that ANCHOR-HCMV fluorescent spots result from

367 the specific accumulation of OR-FP proteins on the corresponding ANCH sequences inserted  
368 in viral genomes.

### 369 **The ANCHOR cassette is stable in the recombinant virus**

370 We have tested the stability of the ANCHOR phenotype after massive amplification from a  
371 single TB40-ANCHOR3 virus up to a stock of  $8 \cdot 10^8$  infectious particles. Viruses of this stock  
372 were used to infect MRC5 cells which were fixed and stained with various anti-HCMV  
373 antibodies at different times post-infection. We found that  $>90\%$  of pp28 (tegument) positive  
374 cells were also positive for OR-GFP revealing that despite an amplification factor of nearly  
375  $10^9$ , less than 10% of the final viruses had lost the ANCHOR phenotype (Results not shown).  
376 It is noteworthy that a similar situation was also observed for the TB40-GFP stock in which  
377 only 95% of the viruses were positive for both UL44 and GFP (Results not shown).

### 378 **Real-time visualization of ANCHOR-HCMV infection in living human cells**

379 TB40-ANCHOR3 viruses were used to infect MRC5 fibroblast for time-lapse imaging of  
380 infection progression in live cells. Diffuse GFP fluorescence attributable to the OR3-GFP  
381 proteins was first detected in the cytoplasm as well as in the nucleus of the infected cells  
382 between 4 and 5 hours pi. This duration likely corresponds to the time required for the virus to  
383 attach and enter a cell, travel to the nucleus and to express its first genes. Interestingly, during  
384 the same lapse of time, infected cells transiently round out before recovering their usual  
385 spindle shape (Supplementary fig. S2). About 16 hours after infection, faint spots can be  
386 detected in the cells' nuclei (Fig.6a). The number of spots increases during the two or three  
387 following days (Fig.6b), but these remain confined in small peculiar areas (Fig.6b) which fuse  
388 at the end (Fig.6c, Supp.Video1). About 72h to 95h pi., depending on cells, a single, large and  
389 well demarcated area containing up to several hundreds of intense spots occupies most of the  
390 nuclear space. This nuclear area is highly reminiscent of the replication compartment (RC)  
391 which has previously been associated with CMV intranuclear inclusion bodies (32) and later



392 defined as the site of viral DNA replication and replication specific protein accumulation (33,  
393 34). To better characterize this specialized area, we performed immunofluorescence staining  
394 of ANCHOR3-HCMV infected cells with anti-UL44 antibodies. UL44 encodes the  
395 polymerase associated processivity factor which is described to be specifically recruited to  
396 RC (34). Results presented in Fig. 7 clearly show that this well demarcated nuclear area  
397 containing most of the spots (and the most intense ones) is also precisely co-stained with the  
398 anti-UL44 antibody, indicating it is indeed the RC. Interestingly, UL44 distribution clearly  
399 evolves during the course of infection but always superimposes to the areas where HCMV  
400 genomes are also observed. This is true at 24 hpi., when viral genomes are still moderately  
401 amplified and present in limited, rather small areas (Fig.7a) but also at 72hpi., when the  
402 different replication zones have fused in a large replication compartment occupying most of  
403 the nucleus (Fig.7b). In addition to the most intense spots observed in the RC, numerous  
404 fainter spots are clearly visible in the rest of the nucleus and in the cytoplasm (Fig.6d) where  
405 they are especially abundant in a large demarcated, rounded region adjacent to the nucleus  
406 72h pi. (Fig.7b). As it is now largely admitted that viral tegument and envelope are acquired  
407 in a specialized cytoplasmic compartment, we tried to better define the zone containing these  
408 cytoplasmic spots by IF staining for tegument (pp28) and envelope (gB) viral proteins . In our  
409 context of viral infection, pp28 presents a punctuate distribution in the whole cell early after  
410 infection (Fig.7c) but after 72h., few pp28 remains in the nucleus while most of it  
411 accumulates in a juxtannuclear region as described by others (Fig.7d) (35). Interestingly, at this  
412 time, numerous faint spots are also present in the very same zone. The same holds true for gB  
413 staining 72hpi. which accumulates in a similar domain where numerous HCMV spots are also  
414 clearly visible (Fig.7e). It is therefore very likely that this structure is the Assembly  
415 Compartment which overlaps the Endoplasmic Reticulum-Golgi-Intermediate Compartment  
416 (ERGIC) where naked capsids acquire their tegument and envelope (36, 37). Interestingly,

417 the HCMV genomes remain well visible in addition to the IF targeted proteins, indicating that  
418 enough GFP protein from the ANCHOR system survive the immune-fluorescence procedure,  
419 in particular fixation, and that the two approaches are therefore compatible allowing analysis  
420 and co-localization of viruses or viral genomes with any cellular or viral protein of interest.  
421 Following the formation of the large unique RC, no appreciable change in viral accumulation  
422 or cellular morphology seems to occur for several hours. However, after this apparent  
423 quiescence or lag period, membrane rearrangements and cytoplasmic “bubbling” appear at  
424 one or both poles of the cell. These events rapidly amplify and suddenly result in cell  
425 fragmentation and death, similar to “blebbing” (38), only leaving fluorescent scraps  
426 (Supplemental video 2 & 3). It is noteworthy that each cell presents its own infection time  
427 course and some cells undergo a complete cycle from fluorescence appearance to “blebbing”  
428 and fragmentation in less time than the lag period between the mature RC and the cytoplasmic  
429 “bubbling” of some others (Supplemental video 4).

430

### 431 **Replicating viral genomes associate with preformed capsids**

432 It is generally accepted that HV replicating genomes associate in the nucleus with preformed  
433 capsids of which the TER complex encoded by UL89, UL56 and UL51 captures and  
434 internalizes viral DNA through the portal complex (UL104) (39, 40). We analyzed cells at  
435 this stage of infection by correlative fluorescence/electron microscopy (Fig.8a). Electron  
436 microscopy revealed different types of capsids (Fig.8b), reminiscent of previously described  
437 A, B and C forms (41) but also possibly other forms (Fig.8c). When merging fluorescence and  
438 electron microscopy images, fluorescent spots and viral capsids nicely superimposed at the  
439 periphery of the RC (Fig.8d). The chosen area (yellow square in Fig.8a) shows four capsids  
440 on the electron-micrograph (Fig.8d), three containing material (type B?) and an empty  
441 looking one. Interestingly, the fluorescence staining type B capsids (which are at the edge of

442 the RC) is weaker than the one associated with the other capsid, but equivalent between type  
443 B capsids, suggesting that these capsids already contain a single viral genome. On the other  
444 hand, the empty capsid could be linked to a replicative structure containing more than one  
445 viral genome.

446

#### 447 **The ANCHOR technology enables quantitative tracking of HCMV infection**

448 The number of ANCHOR spots present in a peculiar cell can be determined using the Image J  
449 particle detector software (Particle detector & tracker). In the cell illustrated in Fig.9, we  
450 detected n=1155 ANCHOR foci, distributed between the RC (n=1005), the remaining non-RC  
451 nucleoplasm (n=16) and the cytoplasm (n=134). Fluorescence intensity of the observed spots  
452 was highly variable (Fig.9a and b) and could be quantified (Fig. 9c) using an approach similar  
453 to the one that enabled precise quantification of E.coli replisomes and yeast telomerase (42).  
454 Briefly, we used the 3D interactive surface plot plugin for ImageJ that converts fluorescence  
455 intensity into arbitrary fluorescence units in the Z axis of the 3D reconstruction. Therefore,  
456 foci are not represented as 2D dots but as 3D peaks where the Z values correspond to  
457 fluorescence intensities. The diffuse background GFP fluorescence in the cytoplasm and the  
458 nucleus (outside the RC) appears in dark blue in Fig.9c and may be assigned a value of 90  
459 arbitrary units (AU) on the color scale of Fig.9. In the same areas, pale blue regions and spots  
460 corresponding to +/-120AU, are also visible with some of the peaks superimposing with the  
461 spots present on Fig 9a and b. Interestingly, the RC itself is delimited by a line of spots of the  
462 same color. Inside the RC, colors are not distributed along a uniform gradient but rather in  
463 well defined successive, concentric zones of which the mean intensity radially decreases from  
464 the center (containing 240 and 210AU spots) to the periphery and which are separated by +/-  
465 30AU (Fig.9c and d). A similar distribution is also observed in ARPE-19 cells (Fig.S3)  
466 suggesting it results from a phenomenon common to all infected cells.

467 **ANCHOR-HCMV is a new tool for rapid and cost-effective assessment of anti-viral**  
468 **compounds**

469 To date, quantitative information about the presence of HCMV or its replication in a sample  
470 mainly relies on qPCR based technologies which, despite being very tedious, remain  
471 indispensable from a clinical point of view (43). For this kind of investigation and  
472 biotechnological applications, the ANCHOR technology also appears as a very promising  
473 alternative. We have analyzed infection kinetics of MRC5 cells in the presence or not of  
474 Ganciclovir, a compound widely used to treat HCMV infection (44, 45, 46). We have  
475 developed an Array-scan based custom algorithm for automated image analysis. To quantify  
476 the viral DNA content of cells infected with our TB40-ANCHOR3 HCMV viruses, this  
477 algorithm is remarkably efficient and enables direct determination of infection and replication  
478 rates per cell and/or per population (Fig.10a). Imaging of Ganciclovir treated cells revealed  
479 drastically reduced viral DNA content. Despite initial appearance of fluorescent particles in  
480 discrete nuclear domains, subsequent massive amplification and RC formation were inhibited  
481 (Fig.S4). Using various concentrations of Ganciclovir, IC<sub>50</sub> was determined to be 2.26  $\mu$ M, a  
482 value within the range measured by other techniques while IC<sub>90</sub> was measured to be  
483 8.435 $\mu$ M (47). When two independent plates were analyzed, intra- and inter-plate variability  
484 was remarkably low with a correlation coefficient of 0,97 (Fig.10b) demonstrating that our  
485 experimental approach is highly reproducible and robust. We next tested infectivity and  
486 response to drug treatment in parallel on two different cell lines: in a pilot experiment, we  
487 found that at an MOI of 0.5, the infection rate of MRC5 cells increased from 15 to 75%  
488 between 24 hours and 10 days p.i. In the presence of 2.5 $\mu$ M Ganciclovir, this increase was  
489 limited to 40% between days 7 and 10, with no effect at 24h p.i., as expected for a drug  
490 blocking the viral polymerase and not the virus entry. In contrast, the infection rate of ARPE-  
491 19 cells infected at an MOI of 0.5 remained constant between 1 and 3% during the entire

492 experiment, with no evident effect of Ganciclovir (Fig.10c). Viral DNA content was reduced  
493 by 95-100% in Ganciclovir treated MRC5 cells 7 or 10 days pi. while surprisingly, in ARPE-  
494 19 cells, the viral DNA content increased until day 7 pi. Despite a slight decrease at day 10  
495 p.i., no effect of Ganciclovir was observed at 2.5 $\mu$ M (Fig.10d) in these cells which required  
496 12.5 $\mu$ M to completely abolish HCMV replication, indicating that sensitivity to Ganciclovir is  
497 cell type dependent (data not shown). The ease of this quantification paves the way for  
498 innovative screening strategies in the search of new anti-viral drugs.

499

## 500 **DISCUSSION**

501 In this study, we describe the first application of the ANCHOR DNA labeling technology to a  
502 virus resulting in ANCHOR-modified HCMVs which allowed follow up and quantification of  
503 HCMV infection and replication kinetics in real time and living cells, from few hours pi. until  
504 lysis of the infected cell. The biology of ANCHOR-HCMVs and parent BAC derived viruses  
505 appears similar with the replication rate of TB40-ANCHOR3 being even more robust (Table2,  
506 Fig.3). This increased replication rate may stem from variations in viral stock titration, but we  
507 may also have selected a virus especially fitting in MRC5 cells during the BAC construction  
508 which comprised cloning and low efficacy transfection steps. However, this TB40-  
509 ANCHOR3 virus seems to behave as expected and to be therefore an acceptable and  
510 representative HCMV with no significant compensatory deletion that have been described to  
511 sometimes affect HCMV-BAC overlong genomes (48). Moreover, TB40-ANCHOR3 viruses  
512 are tegumented, enveloped and contain viral DNA, possibly associated to OR-GFP proteins  
513 (Fig.4). It may seem surprising that a number of OR-FP sufficient to detect a fluorescent spot  
514 enters the capsid because the viral genome is generally supposed to occupy the entire inner  
515 volume of the capsid (49, 50, 51). This number has been estimated around  $n=50$  (52) while  
516 the number of OR-GFP proteins bound to a single ANCH site and around was evaluated to

517  $n \approx \pm 500$  by FCS (23) on a chromosomal site integrated into the genome of a human cell.  
518 Using 1.15 nm (half the distance between concentric layers of packed DNA in ref. 51) and  
519  $0.85 \cdot 10^5$  nm respectively as radius and length of a 250kb viral DNA, the calculated volume of  
520 the viral DNA ( $= 3.53 \cdot 10^5$  cubic nm) is less than the volume of a capsid with a internal radius  
521 of 48-50nm (49) ( $= 4.63 \cdot 10^5 - 5.25 \cdot 10^5$  cubic nm) and the remaining volume could easily  
522 accommodate up to 500 OR-FP proteins that would only occupy an estimated volume of  $5.25$   
523  $\cdot 10^4$  cubic nm. Therefore, volume considerations do not preclude the presence of OR-GFP  
524 proteins inside the capsid even if the mechanism governing their introduction into the capsid  
525 remains unknown. Notwithstanding, the packaging mechanism which creates very high  
526 pressure inside the capsid and is able to adapt the compaction of the DNA to the length of the  
527 genome is not really understood (50). Of note is that OR-GFP can not enter any viral particle  
528 (results to be published elsewhere) indicating that each viral family has its own packaging  
529 specificities. ANCHOR-HCMV viruses are remarkably stable because  $>90\%$  of particles  
530 conserve the ANCHOR phenotype through a  $10^9$  amplification step. Similar results were  
531 obtained with TB40-GFP and non-fluorescent particles could thus simply reflect lack of  
532 expression or partial loss or mutation of any part of the ANCHOR insertion. Further  
533 experiments are needed to discriminate between these two possibilities. It was firmly  
534 established in yeast, drosophila and human cells that OR-FPs bind to their specific target  
535 sequences and form fluorescent spots that are easily visualized by fluorescence microscopy  
536 (21, 22). In this paper, we demonstrate that this is also true in ANCHOR-HCMV infected  
537 cells. While ChIP experiments have shown that OR-GFP proteins specifically bind to the  
538 ANCH sequence of the viral genome, spots are only observed when cells infected with an  
539 ANCHOR-HCMV virus are also expressing the corresponding OR-FP protein. The same OR-  
540 FP protein in presence of a non-ANCHOR virus genome does not form any spot. Therefore,  
541 the spots we observe in this study each represent a cluster of OR-FPs proteins specifically

542 complexed to ANCH (and surrounding) sequences inserted in viral genomes, be they unique  
543 or in a concatemeric form, nude or encapsidated.

544 The first sign of infection of MRC5 cells by ANCHOR-HCMV is appearance of diffuse  
545 fluorescence in the entire cell about 4 to 5 hours pi., attributable to OR-GFP expression. This  
546 fluorescence increases gradually, mainly in the cytoplasm, until about 16h. pi. when one or  
547 few discrete spots, likely corresponding to the original incoming viral genomes, become  
548 visible in the nucleus. From this moment, the complete course of infection can be observed.  
549 These initial spots first multiply in small specific territories within the nucleus, called pre-  
550 replicative sites. As this first modest multiplication occurs rather early during infection, it is  
551 not clear whether the viral polymerase is already expressed and active at this stage or whether  
552 this amplification is performed by cellular polymerases. In HSV1 infected cells, inhibitors of  
553 viral DNA replication block the formation of RC but not of similar pre-replicative sites (53,  
554 54). Interestingly, this also seems to hold true for HCMV as TB40-ANCHOR3 infected  
555 MRC5 cells only present pre-replicative structures but not mature RC when treated with  
556 Ganciclovir (Fig.S4). This initial pre-replicative stage is followed by a massive amplification  
557 step resulting in numerous (several hundreds) very intense spots which, after fusion of the  
558 different viral replication domains, result in a unique large nuclear compartment at about 72h  
559 pi. At this stage, only this compartment is precisely and uniformly stained with an anti-UL44  
560 antibody and thus contains the polymerase associated processivity factor characteristic of the  
561 replication compartment (RC). Interestingly, ANCHOR technology allows quantifying  
562 fluorescence intensity of single spots and discriminating between background and viral  
563 genome associated fluorescence. Spot intensity is highly variable with the brightest spots  
564 being in the RC while those found outside the RC or in the cytoplasm seem homogeneous and  
565 weak. As shown in Fig.10, the diffuse GFP fluorescence background (in dark blue), grossly  
566 corresponding to the cytoplasm of the cell, may be assigned a value of 90 AU and is scattered



567 with spots (in pale blue) corresponding to +/-120AU. The RC is also delimited by a line of  
568 spots of the same color. In the RC itself, colors corresponding to higher fluorescence values  
569 do not form a continuous gradient but vary by discrete steps, separated by +/-30AU. As each  
570 spot corresponds to one or more viral genome(s) and each viral genome contains a single  
571 ANCH target sequence which binds and recruits similar number of OR-FP protein, we assume  
572 that the stepwise variation of the fluorescence intensity correlates with the number of viral  
573 genomes present in each spot. Because spot intensities in the RC vary by steps of 30AU  
574 which is also the value between the background and the less intense spots, it seems logical to  
575 speculate that 30AU is the quantity of fluorescence generated by the OR-GFP proteins  
576 associated to a single viral genome. Therefore, spots of 120, 150, 180, 210 and 240 AU could  
577 correspond to 1, 2, 3, 4 and 5 viral genomes when correcting for the 30AU fluorescence  
578 background. In the RC, this interpretation makes sense to concatemers of varying number of  
579 viral genomes generated by a “rolling circle” replication mechanism and that will  
580 subsequently be cut by the terminase complex after encapsidation of a single genome unit  
581 (55). This “rolling circle” mechanism of lytic replication, similar to phage replication and  
582 widely accepted, has never been formally proven but very nicely fits with our data even if we  
583 cannot exclude other mechanisms involving  $\theta$  structures for instance (1, 56). If this  
584 assumption is correct, low intensity RC, non-RC nuclear and cytoplasmic particles are  
585 probably capsids containing a single viral genome but at different stages of maturation while  
586 bright spots present in the RC and displaying between 150 and 240 FU are replicative  
587 structures harboring between 2 and 5 viral genomes. As already mentioned, the most intense  
588 spots are preferentially localized in the center of the RC and the fluorescence decreases  
589 towards the edge in concentric zones of discrete value (Fig.9c and d). A similar distribution of  
590 spot intensities has also been observed in ARPE19 cells (Supplementary Fig.S3) suggesting  
591 that the RC is highly organized with active replication occurring in the center of the RC and



592 that this organization is a general feature of HCMV replication in infected cells. Then, the  
593 produced concatemeric structures could migrate from the center towards the periphery of the  
594 RC and would progressively be shortened as they encounter the preformed empty capsids of  
595 which the terminase complex cuts out unit long complete genomes which are encapsidated.  
596 Fig.9c suggests that this migration/encapsidation process arrives to completion at the nuclear  
597 membrane which is underlined by a brim of single viral genome spots. Finally, considering  
598 that most of the spots are in the RC and associated with 1 to 5 genomes, one can assume that  
599 such an infected cell contains at this precise moment 3000 to 5000 viral genomes. It is  
600 noteworthy that qPCR titration of viral genomes yield values ranging from eight to twenty  
601 thousand viral genomes per infected cell (Table 2). We consider these two sets of values based  
602 on spot counting and fluorescence intensity remarkably coherent especially as they  
603 correspond to instantaneous (fluorescence) and cumulative (qPCR) measurements.

604 Once synthesized, the viral genomes have to enter capsids which are assembled in the nucleus  
605 from the different capsid proteins imported from the cytoplasm. With their portal complex,  
606 capsids are able to cleave the genome concatemers resulting from the rolling circle  
607 mechanism and to internalize a single unit length genome through an ATP dependant  
608 mechanism (39). When analyzing the RC by correlation fluorescence/electron microscopy,  
609 unexpected results were obtained, suggesting that the classical capsid classification in A, B  
610 and C forms is possibly oversimplified. By analyzing numerous pictures (Fig.8 and results not  
611 shown), it appears that capsids that could be classified as C forms are rare and much less  
612 frequent than described (41). On the other hand, some capsids containing dense fragmented  
613 material are also clearly visible on Fig.8c. Of course, all these results could simply reflect the  
614 different conditions of infection and sample treatment, but could also indicate that more  
615 capsid forms exist which need to be understood. Whatever their significance, the three capsids  
616 on the left of figure 8d (marked with white arrows) are associated to three spots of equal

617 intensity, but less intense than the spot on the right of the same picture. This association could  
618 of course be fortuitous but it is also tempting to speculate that these three spots represent  
619 capsids which have internalized one single viral genome and which are ready to leave the RC.  
620 The fourth capsid which appears empty in electron microscopy is in close contact with a  
621 stronger fluorescent signal and could thus be associated with a replicating, concatameric  
622 structure. However, the three capsids showing weak fluorescence resemble type B capsids,  
623 considered to be devoid of genetic material. This interpretation therefore remains highly  
624 speculative but, on the other hand, simple random association is also hard to imagine. As  
625 Fig.8c suggests there may exist other intermediate forms of capsids, it is possible that type B  
626 is a heterogeneous population of which a fraction could contain DNA.

627 Once capsids have loaded a viral genome, they leave the RC and the nucleus toward the  
628 cytoplasm. ANCHOR technology allows precise counts of the genomes present in different  
629 parts of the cell as illustrated in Fig.9. Due to their fluorescence values, we think that spots  
630 present in the nucleus outside the RC and in the cytoplasm correspond to single encapsidated  
631 genomes contrary to spots observed in the RC. If this interpretation is correct, there are  
632 significantly less viral genomes in the non-RC nucleoplasm and the cytoplasm than in the RC,  
633 possibly around 1% or less. Interestingly, when titers of virus stocks are plotted against the  
634 number of producing cells, obtained numbers are closer of what is found in the cytoplasm  
635 than in the RC, suggesting that most of the genomes synthesized in the RC could be lost.  
636 Therefore, the passage from the RC towards the cytoplasm could be a significant “bottleneck”  
637 in virus production even if the very low number of spots observed in the non-RC nucleoplasm  
638 could argue for the RC exit being the real limiting step. It is also possible that once  
639 encapsidated with the viral genome, fluorescence intensity of OR-FP is reduced and that only  
640 a minute fraction of the mature viruses remain visible. Reduced fluorescence of the  
641 encapsidated viral genome could be due to loss of OR-FP molecules during the encapsidation

642 process. Cytoplasmic spots seen in Fig.9 are coherent with this hypothesis as they are clearly  
643 detected in Fig.9 a and b due to their fluorescence although they do not reach the threshold of  
644 120 fluorescence AU. However, a cluster of 50-100 OR-FP proteins is already detectable and  
645 it is therefore logical to find in the cytoplasm spots with intensities ranging between  
646 background and 120AU. This may also explain why we were so far unable to visualize  
647 incoming viruses during the very first hours pi. although these could simply have been missed  
648 due to the extremely low probability to detect them in the adequate focal plane. A large  
649 proportion of the spots found in the cytoplasm are preferentially gathered in a faintly  
650 demarcated region close to the nucleus. As this region is stained by anti-pp28 and anti-gB  
651 antibodies (Fig.7), it very likely represents a viral Assembly Compartment where the capsids  
652 acquire their tegument and envelope and which overlaps the Endoplasmic Reticulum-Golgi-  
653 Intermediate Compartment (ERGIC) (35, 36, 37). In the rest of the cytoplasm, spots are  
654 fainter and their observation necessitates boosting the image acquisition conditions, leading to  
655 RC signal saturation. Finally, the way new viruses leave the cell remains so far unclear and  
656 possibly, particles could also be directly transferred from one cell to another neighboring one  
657 without any extracellular step. Alternatively, time lapse imaging of infected cells also  
658 revealed sudden “blebbing” and fragmentation of infected cells. This “blebbing” is often  
659 considered as indicative of apoptosis (38) but the mechanism of fragmentation ending cell  
660 infection is poorly understood. As the timing of this fragmentation is significantly delayed by  
661 the potent suppressor of apoptosis vMIA encoded by the UL37x1 viral gene, it is likely that  
662 longer infection time is advantageous for the virus and that fragmentation, on the contrary,  
663 interrupts the viral cycle and allows release of alarm signals to neighboring cells (57).  
664 Interestingly, this ultimate step occurred at very different times in different cells and generates  
665 numerous highly fluorescent cell fragments which thus possibly contain viral DNA. It will be  
666 of great interest to further explore this process to determine whether it may contribute to virus

667 dissemination or whether it is the ultimate cellular defense bypassing the final maturation  
668 steps of the viruses and releasing non infectious although immunogenic material.

669 From a biotechnological point of view, ANCHOR-HCMV viruses are a remarkable tool to  
670 characterize antiviral compounds. As a proof of concept, we have measured the effect of  
671 Ganciclovir on the infection of various cell lines with ANCHOR3-HCMV. With very limited  
672 hands-on investment, we have been able to establish IC50 and IC90 of this drug on the  
673 HCMV infection of MRC5 human fibroblasts, simply recording fluorescence variation using  
674 an automated Arrayscan microscope (Fig.10). The results we obtained were highly  
675 reproducible and coherent with values already published (47). We performed the same  
676 experiment on the retina epithelial ARPE-19 cell line, with totally different results. These  
677 cells are indeed much less efficiently infected by the ANCHOR-HCMV TB40 virus, and the  
678 course of infection does not seem to be modified by Ganciclovir, suggesting that the drug is  
679 not metabolized in the same manner in MRC5 and ARPE-19 cells. For instance,  
680 phosphorylation of this drug by cellular kinases may be less efficient in ARPE-19 cells.  
681 Alternatively, higher drug concentrations may be needed as suggested by the loss of HCMV  
682 replication in these cells in the presence of 12.5 $\mu$ M Ganciclovir. Whichever the reasons  
683 underlying the different responses of different cell lines to Ganciclovir, these results indicate  
684 that ANCHOR-HCMV viruses will permit rapid and cost effective screening of large libraries  
685 of chemicals for the search of new anti-viral activities, including measurements of several  
686 parameters as toxicity of the compound, infection rate, virus DNA replication level and  
687 infection propagation without any fixation, extraction or reagent. Using ANCHOR-HCMV  
688 and automated high content microscopy, it will be easy to screen even large collections of  
689 chemical compounds. Furthermore, this technology can be used to label other DNA viruses  
690 for which we already have proofs of concept (results to be published elsewhere).

691 In addition to new insights into fundamental biology of numerous DNA viruses, ANCHOR  
692 technology is amenable to high throughput imaging, with high confidence over long time  
693 series of multiple cell lines, under different biological conditions in parallel. The technology  
694 is therefore particularly suited to rapid testing compound concentrations, stability and  
695 administration conditions for the design of new and/or combinatorial antiviral treatments. For  
696 all these reasons, the ANCHOR technology appears as a highly promising tool for  
697 fundamental research but also for numerous biotechnology applications.

698

## 699 **BIBLIOGRAPHY**

- 700 1. Mocarski EJ, Shenk T, Pass RF. 2007. Cytomegaloviruses. *In* Fields Virology, 5th  
701 Edition, Philadelphia, PA., Knipe DM. and Howley PM. Editors; Lippincott, Williams,  
702 Wilkins, p2703-2774.
- 703 2. Staras SAS, Flanders WD, Dollard SC, Pass RF, McGowan JEJ, Cannon MJ. 2008.  
704 Influence of sexual activity on cytomegalovirus seroprevalence in the United States,  
705 1988-1994. *Sex Transm Dis* 35(5):472–479.
- 706 3. Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence  
707 and demographic characteristics associated with infection. *Rev Med Virol.*  
708 Jul;20(4):202-13.
- 709 4. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of  
710 congenital cytomegalovirus (CMV) infection. *Rev Med Virol.* Jul-Aug;17(4):253-76.
- 711 5. Kari B, Gehrz R. 1992. A human cytomegalovirus glycoprotein complex designated  
712 gC-II is a major heparin-binding component of the envelope. *J Virol.* Mar; 66(3):1761-  
713 4.

- 714 6. Söderberg C, Giugni TD, Zaia J a, Larsson S, Wahlberg JM, Möller E. 1993. CD13  
715 (human aminopeptidase N) mediates human cytomegalovirus infection. *J Virol* 67(11)  
716 :6576–85.
- 717 7. Pietropaolo RL, Compton T. 1997. Direct interaction between human cytomegalovirus  
718 glycoprotein B and cellular annexin II. *J Virol* 71(12) :9803–9807.
- 719 8. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houlès C, Fieschi F,  
720 Arenzana-Seisdedos F, Moreau JF, Déchanet-Merville J. 2002. Human  
721 Cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target  
722 cell trans-infection. *Immunity* 17(5) :653–664.
- 723 9. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. 2003. Epidermal growth  
724 factor receptor is a cellular receptor for human cytomegalovirus. *Nature* 424(6947)  
725 :456–461.
- 726 10. Kabanova A, Marcandalli J, Zhou T, Bianchi S, Baxa U, Tsybovsky Y, Lilleri D,  
727 Silacci-Fregni C, Foglierini M, Fernandez-Rodriguez BM, Druz A, Zhang B, Geiger R,  
728 Pagani M, Sallusto F, Kwong PD, Corti D, Lanzavecchia A, Perez L. 2016. Platelet-  
729 derived growth factor- $\alpha$  receptor is the cellular receptor for human cytomegalovirus  
730 gHgLgO trimer. *Nat Microbiol.* Jun 6;1(8):16082. doi: 10.1038/nmicrobiol.2016.82.
- 731 11. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. 1995. Fibroblasts,  
732 epithelial cells, endothelial cells and smooth muscle cells are major targets of human  
733 cytomegalovirus infection in lung and gastrointestinal tissues. *J Gen Virol* 76 ( Pt  
734 4):741–750.
- 735 12. Mendelson M, Monard S, Sissons P, Sinclair J. 1996. Detection of endogenous human  
736 cytomegalovirus in CD34+ bone marrow progenitors. *J Gen Virol* 77(Pt 12) :3099–  
737 3102.

- 738 13. Rust MJ, Lakadamyali M, Brandenburg B, Zhuang X. 2011. Single-virus tracking in  
739 live cells. *Cold Spring Harb Protoc* 2011(9):1042–1056.
- 740 14. Sun E, He J, Zhuang X. 2013. Live cell imaging of viral entry. *Curr Opin Virol.* 3(1)  
741 :34–43.
- 742 15. Sivaraman D, Biswas P, Cella LN, Yates M V, Chen W. 2011. Detecting RNA viruses  
743 in living mammalian cells by fluorescence microscopy. *Trends Biotechnol* 29(7) :307–  
744 13.
- 745 16. Smith G.A., Gross S.P., Enquist L.W. 2001. Herpes viruses use bidirectional fast  
746 axonal transport to spread in sensory neurons. *PNAS.* 98(6), 3466-3470.
- 747 17. Luker G.D., Prior J.L., Song J., Pica C.M., Leib D.A. 2003. Bioluminescence Imaging  
748 reveals systemic dissemination of Herpes Simplex Virus Type 1 in the absence of  
749 Interferon Receptor. *J Virol.* 77(20), 11082-11093.
- 750 18. Sampaio KL, Cavnignac Y, Stierhof Y-D, Sinzger C. 2005. Human cytomegalovirus  
751 labeled with green fluorescent protein for live analysis of intracellular particle  
752 movements. *J Virol* 79(5):2754–2767.
- 753 19. Bystricky K, Gallardo F, Lane D, Dubarry N. 2012. Constructs and method for  
754 regulating gene expression or for detecting and controlling a DNA locus in eukaryotes.  
755 WO/2012/127047.
- 756 20. Graham TGW, Wang X, Song D, Etson CM, van Oijen AM, Rudner DZ, Loparo JJ.  
757 2014. ParB spreading requires DNA bridging. *Genes Dev* 28(11) :1228–1238.
- 758 21. Sanchez A, Cattoni DI, Walter J-C, Rech J, Parmeggiani A, Nollmann M, Bouet J-Y.  
759 2015. Stochastic Self-Assembly of ParB Proteins Builds the Bacterial DNA  
760 Segregation Apparatus. *Cell Syst* 1(2):163–173.
- 761 22. Saad H, Gallardo F, Dalvai M, Tanguy-le-Gac N, Lane D, Bystricky K. 2014. DNA

- 762 Dynamics during Early Double-Strand Break Processing Revealed by Non-Intrusive  
763 Imaging of Living Cells. PLoS Genet 10(3), e1004187.
- 764 23. Germier T., Kocanova S., Bancaud A., Walthers N., Sellou H., Shaban H., Ellenberg J.,  
765 Gallardo F. and Bystricky K. 2017. “Real-time chromatin dynamics of the single gene  
766 level during transcription activation” doi: <https://doi.org/10.1101/111179>  
767 <http://biorxiv.org/content/early/2017/02/23/111179>.
- 768 24. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H,  
769 Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly  
770 productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E.  
771 J Gen Virol 89(Pt2):359–368.
- 772 25. Borst E., Hahn G., Koszinowski U.H., Messerle M. 1999. Cloning of the Human  
773 Cytomegalovirus (HCMV) genome as an infectious Bacterial Artificial Chromosome in  
774 Escherichia coli : a New Approach for construction of HCMV Mutants. J Virol. 73(10):  
775 8320-8329.
- 776 26. Britt, W.J. Human Cytomegalovirus : Propagation, Quantification, and Storage. (2010)  
777 *In* Current Protocols in Microbiology 14E.3.1-14E.3.17.  
778 Published online August 2010 in Wiley Interscience ([www.interscience.wiley.com](http://www.interscience.wiley.com)).
- 779 27. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. 2003. Estrogen  
780 receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on  
781 a natural target promoter. Cell.115(6):751–763.
- 782 28. Wickham H. 2009. ggplot2: elegant graphics for data analysis. Springer, New York,  
783 NY.
- 784 29. Polishchuk RS, Mironov AA. 2001. Correlative video light/electron microscopy. Curr  
785 Protoc Cell Biol. Chapter 4:Unit 4.8.



786

787 30. Keene DR, Tufa SF, Wong MH, Smith NR, Sakai LY, Horton WA. 2014. Correlation  
788 of the same fields imaged in the TEM, confocal, LM, and microCT by image  
789 registration: from specimen preparation to displaying a final composite image. *Methods*  
790 *Cell Biol.*124:391-417.

791 31. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B. 2011. HCMV spread  
792 and cell tropism are determined by distinct virus populations. *PLoS Pathog.* Jan  
793 13;7(1):e1001256. doi: 10.1371/journal.ppat.1001256.

794

795 32. Kanich, R. E. and Craighead J. E. 1972. Human cytomegalovirus infection of cultured  
796 fibroblasts. II. Viral replicative sequence of a wild and an adapted strain. *Lab.Invest.*27,  
797 273-282.

798 33. Fons M.P., Graves K., Cavallo T., Pollard R., Albrecht T. 1986. Human  
799 cytomegalovirus : Development and progression of nuclear inclusions by primary  
800 clinical isolates and laboratory-adapted strains. *Proc. Soc. Exp. Biol. Med.* 181(3), 416-  
801 422.

802 34. Penfold M.E.T. and Mocarski E.S. 1997. Formation of Cytomegalovirus DNA  
803 Replication Compartments Defined by Localisation of Viral Proteins and DNA  
804 Synthesis. *Virology* 239, 46-61.

805 35. Sanchez V., Greis K.D., Sztul E., Britt W.J. 2000. Acculument of virion tegument  
806 and envelope proteins in a stable cytoplasmic compartment during human  
807 cytomegalovirus replication : characterization of a potential site of virus assembly. *J.*  
808 *Virol.* 74(2), 975-986.

- 809 36. Sanchez V., Sztul E., Britt W.J. 2000. Human cytomegalovirus pp28 (UL99) localizes  
810 to a cytoplasmic compartment which overlaps the endoplasmic Reticulum-Golgi-  
811 Intermediate compartment. *J.Virol.* 74(8): 3842-3851.
- 812 37. Das S, VasANJI A, Pellett PE. 2007. Three-Dimensional Structure of the Human  
813 Cytomegalovirus Cytoplasmic Virion Assembly Complex Includes a Reoriented  
814 Secretory Apparatus. *J Virol* 81(21):11861–11869.
- 815 38. Charras GT. 2008. A short history of blebbing. *J Microsc* 231(3):466–478.
- 816 39. Dittmer A, Drach JC, Townsend LB, Fischer A, Bogner E. 2005. Interaction of the  
817 putative human cytomegalovirus portal protein pUL104 with the large terminase  
818 subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. *J Virol.*  
819 79(23),14660-7.
- 820 40. Britt B. 2007. Maturation and egress. In " Human Herpesviruses: Biology, Therapy,  
821 and Immunoprophylaxis." Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS,  
822 Roizman B, Whitley R, Yamanishi K, editors. Cambridge University Press; 2007.  
823 Chapter 20.
- 824 41. Tandon R, Mocarski ES, Conway JF. 2015. The A, B, Cs of herpesvirus  
825 capsids. *Viruses*,7(3): 899-914.
- 826 42. Gallardo F, Laterreur N, Cusanelli E, Ouenzar F, Querido E, Wellinger RJ, Chartrand,  
827 P. 2011. Live cell imaging of telomerase RNA dynamics reveals cell cycle-dependent  
828 clustering of telomerase at elongating telomeres.  
829 *Mol Cell.*: 44(5):819-27.
- 830 43. Najjioullah F, Thouvenot D, Lina B. 2001. Development of a real-time PCR procedure  
831 including an internal control for the measurement of HCMV viral load. *J Virol*  
832 *Methods* 92(1):55–64.

- 833 44. Erice A., Jordan M. C., Chace B.A., Fletcher R. N. C., Pharm D., Chinnock, B.J.  
834 Balfour H.H.Jr. 1987. Ganciclovir Treatment of Cytomegalovirus Disease in  
835 Transplant Recipients and Other Immunocompromised Hosts. *JAMA*. 257(22):3082-  
836 3087.
- 837 45. Gerna G., Zipeto D., Parea M., Revello M.G., Silini E., Percivalle E., Zavattoni M.,  
838 Grossi P., Milanesi G. 1991. Monitoring of Human Cytomegalovirus Infection and  
839 Ganciclovir Treatment in Heart Transplant Recipients by Determination of Viremia,  
840 Anigenemia and DNAemia. *J. Infect. Diseases*. 164(3) : 488-98.
- 841 46. Whitley R.J., Cloud G., Gruber W., Storch G.A., Demmler G.J., Jacobs R.F., Dankner  
842 W., Spector S.A., Starr S., Pass R.F., Stagno S., Britt W.J., Alford C., Soong S.-J.,  
843 Zhou X.-J., Sherril L., FitzGerald J.M., Sommadossi J.-P. National Institute of Allergy  
844 and Infectious Diseases Collaborative Antiviral Study Group. 1997. Ganciclovir  
845 Treatment of Symptomatic Congenital Cytomegalovirus Infection : Results of a Phase  
846 II Study. *J. Infect.Diseases*. 175(5):1080-6.
- 847 47. Boivin G., Erice A., Crane D. D., Dunn D. L.,Balfour H.H.Jr. 1993. Ganciclovir  
848 Susceptibilities of Cytomegalovirus (CMV) Isolates from Solid Organ Transplant  
849 Recipients with CMV Viremia after Antiviral Prophylaxis. *J.Infect.Diseases*.168( 2):  
850 332-335.
- 851 48. Murrell I, Wilkie GS, Davison AJ, Statkute E, Fielding CA, Tomasec P, Wilkinson  
852 GW, Stanton RJ. 2016. Genetic Stability of Bacterial Artificial Chromosome-Derived  
853 Human Cytomegalovirus during Culture In Vitro. *J Virol*. 28;90(8):3929-43.

- 854 49. Butcher SJ, Aitken J, Mitchell J, Gowen B, Dargan DJ. 1998 Structure of the human  
855 cytomegalovirus B capsid by electron cryomicroscopy and image reconstruction. *J*  
856 *Struct Biol.* Dec 1;124(1):70-6.
- 857 50. Bhella D, Rixon FJ, Dargan DJ. 2000. Cryomicroscopy of human cytomegalovirus  
858 virions reveals more densely packed genomic DNA than in herpes simplex virus type  
859 1. *J Mol Biol.* Jan 14;295(2):155-61.
- 860 51. Yu X, Jih J, Jiang J, Zhou ZH. 2017. Atomic structure of the human cytomegalovirus  
861 capsid with its securing tegument layer of pp150. *Science.* Jun 30;356(6345).
- 862 52. Fusco D., Accornero N., Lavoie B., Shenoy SM., Blanchard JM., Singer RH., Bertrand  
863 E. 2003. Single mRNA molecules demonstrate probabilistic movement in living  
864 mammalian cells. *Curr Biol.* Jan 21;13(2):161-167.
- 865 53. de Bruyn Kops A, Knipe DM. 1988. Formation of DNA replication structures in herpes  
866 virus-infected cells requires a viral DNA binding protein. *Cell.*55(5),857-68.
- 867 54. Lukonis CJ, Weller SK. 1996. Characterization of nuclear structures in cells infected  
868 with herpes simplex virus type 1 in the absence of viral DNA replication. *J*  
869 *Viro.*70(3):1751-8.
- 870 55. McVoy MA, Adler SP. 1994. Human cytomegalovirus DNA replicates after early  
871 circularization by concatemer formation, and inversion occurs within the concatemer.  
872 *J Virol.* 68(2):1040-51.
- 873 56. McGeoch DJ. 1987. The genome of herpes simplex virus: structure, replication and  
874 evolution. *J Cell Sci Suppl.*7:67-94.

875 57. McCormick AL, Roback L, Mocarski ES. 2008 HtrA2/Omi terminates  
876 cytomegalovirus infection and is controlled by the viral mitochondrial inhibitor of  
877 apoptosis (vMIA). PLoS Pathog. May 9;4(5):e1000063. doi:  
878 10.1371/journal.ppat.1000063.

879

## 880 **ACKNOWLEDGMENTS**

881 We thank Eva Borst and Martin Messerle for the CMV TB40-GFP BAC construct and  
882 various plasmids. We greatly benefitted from the expertise of Sylvain Cantaloube at the TRI  
883 Imaging platform (IBCG) and of Jacques Rouquette at the ITAV imaging facility. We are also  
884 deeply indebted to Professor Henri Agut for critical reading of this manuscript. This work was  
885 supported by “Fondation ARC”, grant n° HFSPO RGP0044, and by a development project of  
886 “Toulouse Tech Transfer”.

## 887 **FIGURES AND TABLES LEGENDS**

### 888 **Table 1. Measure of the TB40-ANCHOR3 HCMV stock virus titer.**

889 Titer was measured using a classical plaque forming assay and a fluorescence assay. See  
890 Material and Methods for details. Whatever the technique, measured titers are significantly  
891 higher when infection time is increased from 2h to 18 h. However, very similar results are  
892 obtained with both techniques.

### 893 **Table 2. Replication kinetics of TB40-GFP and TB40-ANCHOR3 viruses.**

894 MRC5 cells were infected at an MOI of 0.2. Cells and supernatants were harvested on days 2,  
895 4, 6, 8 and 10 post-infection and DNA purified from each sample. Total numbers of viral  
896 genomes were determined for each sample using qPCR. Cells and infected cells were counted  
897 in a parallel plate. Each measure was made in triplicate and mean values of the two wells per  
898 time point are given for each day (except for day 10 pi.).

899 **Figure 1. Principle of the ANCHOR DNA labeling technology.**

900 a)The ANCHOR system is composed of an ANCH DNA target sequence less than 1kb long  
901 (red box) which specifically binds dimers of OR protein through nucleation sites. This  
902 binding is dynamic and bound dimers spread on the DNA while further OR dimers are  
903 recruited to form a large metastable nucleoprotein complex. When OR protein is fused to a  
904 fluorescent marker (green circles), accumulation of this complex on the ANCH sequence  
905 forms a spot which is easily detected by fluorescence microscopy. The ANCH sequence and a  
906 chimaeric gene encoding the corresponding OR protein fused to a fluorescent protein may be  
907 cloned together in a cassette that can be inserted in a site specific manner into the target viral  
908 genome as described in fig.2. ; b) TB40-ANCHOR3 infected MRC5 cells, 48h pi. showing  
909 accumulation of fluorescent spots in the nucleus.

910 **Figure 2. Construction of the ANCH2 or ANCHOR3 HCMV BAC used in this study and**  
911 **characterization of viruses derived from the TB40-ANCHOR3 HCMV BAC.**

912 Both ANCH2 and ANCHOR3 HCMV BAC were derived from the TB40-gfp BAC which  
913 contains the GFP gene under the control of a murine CMV immediate early promoter  
914 (pMCMV-MIEP-GFP) inserted in the vector backbone. This gene was replaced by the desired  
915 constructs without affecting any other viral gene or sequence. The TB40-ANCH2-Kana  
916 HCMV BAC displaying a single ANCH2 target sequence has been obtained by exchanging  
917 the MCMV-MIEP-GFP gene with an ANCH2-Kana<sup>R</sup> cassette while the MCMV-MIEP-GFP  
918 gene has been exchanged by homologous recombination with a Kana<sup>R</sup> –OR3/GFP-ANCH3  
919 cassette to create the TB40-ANCHOR3 HCMV BAC.

920 **Figure 3. Replication curves of TB40-GFP or TB40-ANCHOR3 viruses in MRC5**  
921 **infected cells.** a) Titration of HCMV genomes in the supernatants of infected cells, compared  
922 to published growth kinetics of TB40-BAC4 viruses measured by TCID50 in HFF cells (31);

923 b) Titration of HCMV genomes in MRC5 infected cells. Measured or calculated values  
924 (TB40-BAC4) are given at the bottom of each figure.

925 **Figure 4. Characterization of TB40-ANCHOR3 viruses .**

926 Viral particles derived from the TB40-ANCHOR3 HCMV BAC contain DNA, OR3-GFP  
927 proteins and stain for pp28 tegument proteins (a) and for gB envelope proteins (b); they likely  
928 correspond to mature viruses with OR proteins bound to the encapsidated genomes. Images  
929 acquired with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 63X

930 **Figure 5. OR-FP specifically bind to their target ANCH sequence generating the spots**  
931 **observed in fluorescence microscopy.**

932 a)ChIP experiment showing that Chromatin extracted from TB40-ANCHOR3 HCMV  
933 infected MRC5 cells (but not from TB40-GFP Infected cells) and immunoprecipitated with  
934 anti-GFP antibody is only enriched in ANCH3 and GFP sequences; hatched section  
935 corresponds to background noise, since no ANCH3 sequence is present in the TB40-GFP  
936 virus.; b) MRC5 cells were transfected with a single vector expressing OR2-GFP and then  
937 infected or not with TB40-ANCH2-Kana viruses; spots appear only when OR-FP and the  
938 corresponding ANCH target sequences on the viral genomes are present simultaneously in the  
939 same cell. Images aquired 24 h post transfection and 72h post infection with a wide-field  
940 Zeiss Axiovert, Observer Z1, 1.4NA objective 63X or a Zeiss LSM 510 NLO; c) MRC5 cells  
941 were transfected with an expression vector for OR3-mCherry or infected with TB40-GFP or  
942 transfected and infected simultaneously; no spot are observed in any situation indicating that  
943 nor OR3 proteins neither TB40-GFP genomes form unspecific spots, even when present  
944 simultaneously in the same cell. Images aquired 24 h post transfection and 72h post infection  
945 with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 63X or a Zeiss LSM 510  
946 NLO.

947 **Figure 6. Visualization of ANCHOR -HCMV infection steps in living cells.**

948 MRC5 cells were infected with TB40-ANCHOR3 HCMV viruses at an MOI of 0.5; a) about  
949 16-17 hours pi, some very faint spots appear in infected cells which possibly correspond to  
950 incoming viral genomes (white arrows, 63X); b) distinct areas suggestive of pre-replicative  
951 sites develop around the initial spots which multiply while these areas increase in size (white  
952 arrows, 63X); c) later in infection (around 70-80h pi.), these areas fuse in a unique putative  
953 replication compartment (RC) which continues to grow (40X, scale bar 10 $\mu$ m); d) an infected  
954 MRC5 cell imaged 72h pi.: the nucleus contains a large replication compartment (RC) with  
955 numerous brilliant spots (red triangles) while fainter spots are visible in the nucleus outside  
956 the RC (black triangles) and in the cytoplasm (white triangles)(63X). All images acquired  
957 with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 40X or 63X.

958 **Figure 7. The putative replication compartment stains for the polymerase associated**  
959 **processivity factor pUL44 while pp28 and gB proteins accumulate in a region close to**  
960 **the nucleus suggestive of the Assembly Compartment.**

961 TB40-ANCHOR3 HCMV infected MRC5 cells were stained for pUL44 at different times pi.  
962 a) 24h pi. b) At 72h pi., only the putative RC is positive for pUL44 confirming its status. For  
963 each time point, upper left: Hoechst 33342, upper right: OR-GFP fluorescence, lower left:  
964 anti-pUL44, lower right: merge. TB40-ANCHOR3 HCMV infected MRC5 cells were stained  
965 for the pp28 tegument protein at different times pi. (c and d) or for the envelope gB protein  
966 (e). c) 24h pi., pp28 is already expressed but appears diffuse in the whole cell. d) On the  
967 contrary, 72h pi., pp28 is concentrated in a large region close to the nucleus where OR-GFP  
968 spots are also visible suggesting this region is the Assembly Compartment. For each time  
969 point, upper left: Hoechst 33342, upper right: OR-GFP fluorescence, lower left: anti-pp28,  
970 lower right: merge. e) TB40-ANCHOR3 HCMV infected MRC5 cells were stained for the gB  
971 envelope protein 72h pi. showing accumulation in a region close to the nucleus, especially in



972 the central area of this region; upper left: Hoechst 33342, upper right: OR-GFP fluorescence,  
973 lower left: anti-gB, lower right: merge.

974 **Figure 8. Visualization of infected cell by correlative fluorescence-electron microscopy.**

975 a) Cells infected with TB40-ANCHOR3 HCMV were first analyzed by fluorescence  
976 microscopy 96h pi. and then fixed and processed for electron microscopy examination (scale  
977 bar 2 $\mu$ m). The zone delimited by a yellow square has been further analyzed with higher  
978 magnification in d); b) in the RC, electron microscopy reveals different forms of capsids,  
979 resembling the typical type A, B and C capsids respectively shown by black, red and white  
980 arrows (scale bar 200nm); c) at higher magnification, other, possibly more diverse, forms of  
981 capsids seem to appear, some containing dense fragmented material (white arrows); d) in the  
982 chosen area (corresponding to yellow box in a), 4 capsids are observed by EM, which all  
983 correspond to fluorescent spots. Three appear as B forms (white arrows) while the fourth is a  
984 A form (red arrow). Spots associated with the three type B capsids present similarly weak  
985 intensities suggesting they contain a single viral genome. On the contrary, the type A capsid  
986 coincides with a much brighter spot and could be associated to a replicating structure with  
987 several genomes (scale bar 500nm).

988 **Figure 9. ANCHOR technology allows quantification of HCMV infection in live cells.**

989 a) Fluorescent spots in an MRC5 cell infected with TB40-ANCHOR3 HCMV 72h pi.; as  
990 demonstrated above, each spot corresponds to one or several fused genomes; b) same image  
991 as a) but treated to filter out the fluorescence background and then processed using spot  
992 detector plugin for ImageJ (spot radius 2, cutoff 0, percentile 7) allowing detection of 1155  
993 ANCHOR foci: 1005 particles in the RC, 16 nuclear particles outside of RC and 134  
994 cytoplasmic particles; c) images were then converted into 3D intensity surface plot  
995 (perspective) or, d) into a picture in X,Z to assess particles intensity. A single viral genome  
996 corresponds to 30 arbitrary fluorescence units (FU). In the RC, all spots harbor between 2 and


997 5 viral genomes and this number decreases from the center to the periphery, suggesting a  
998 highly organized territory. Outside the RC, only unique genomes are observed (see text for  
999 explanations).

1000 **Figure 10. Cell type specific effect of Ganciclovir on TB40-ANCHOR3 HCMV infection**  
1001 **and IC50 determination by automated high content imaging.**


1002 a) TB40-ANCHOR3 HCMV infected cells were treated or not with 12.5 $\mu$ M Ganciclovir. 72  
1003 hours pi, cells were observed using a Thermo Scientific Cellomics Arrayscan Vti microscope  
1004 and images analyzed with the compartmental analysis algorithm allowing detection of viral  
1005 DNA (in red, see Material and Methods for explanation); b) similar experiment as a) but  
1006 TB40-ANCHOR3 HCMV infected cells were treated with increasing doses of Ganciclovir.  
1007 Results of the quantification were plotted against Ganciclovir concentrations (see text)  
1008 allowing precise determination of IC50 and IC90. Two identical experiments were performed  
1009 on separate plates (A and B); c) time course of TB40-ANCHOR3 HCMV infections in MRC5  
1010 or ARPE-19 cells, in the presence or not of 2.5 $\mu$ M Ganciclovir. In MRC5 cells, infection  
1011 progresses to reach more than 70% infected cells 10 days pi and this infection is partly  
1012 controlled by Ganciclovir. ARPE-19 cells do not seem to be highly permissive and 2 to 3% of  
1013 the cells only become infected, in the presence or not of Ganciclovir; d) same experiment as  
1014 in c) but using viral DNA quantification as a read-out.

**Fig. 1**

**a**




**b**



**Figure 1.** a) Principle of the ANCHOR DNA labeling technology : the ANCHOR system is composed of an ANCH DNA target sequence less than 1kb long (red box) which specifically binds dimers of OR protein through nucleation sites. Bound dimers spread on the DNA while further OR dimers are recruited to form a large metastable nucleoprotein complex. When OR protein is fused to a fluorescent marker (green circles), accumulation of this complex on the ANCH sequence forms a spot which is easily detected by fluorescence microscopy; b) TB40-ANCHOR3 infection of MRC5 cells 72h pi.: the nucleus contains a large replication compartment (RC) with numerous brilliant spots (red arrows) while fainter spots are visible in the nucleus outside the RC (white arrows) and in the cytoplasm (black arrows)(63X). All images acquired with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 63X.

**Fig. 2**




**Figure 2. Construction of the ANCH2 or ANCHOR3 HCMV BAC used in this study.**

Both ANCH2 and ANCHOR3 HCMV BAC were derived from the TB40-GFP BAC which contains the GFP gene under the control of a murine CMV immediate early promoter (pMCMV-MIEP-GFP) inserted in the vector backbone. This gene was replaced by the desired constructs without affecting any other viral gene or sequence. The TB40-ANCH2-Kana HCMV BAC displaying a single ANCH2 target sequence has been obtained by exchanging the MCMV-MIEP-GFP gene with an ANCH2-Kana<sup>R</sup> cassette while the MCMV-MIEP-GFP gene has been exchanged by homologous recombination with a Kana<sup>R</sup> –OR3/GFP-ANCH3 cassette to create the TB40-ANCHOR3 HCMV BAC.

**Fig.3**

**a**



**b**






Figure 3. Replication of TB40-ANCHOR3 (A3) in infected cells. a) Titrations in the supernatants of TB40-BAC4 viruses compared to published titers in HFF cells (31); b) Titrations of TB40-A3O3 genomes in MRC5 infected cells or calculated values (Titration) at the bottom of each figure.

**Fig.4**

**a**







**b**



**Figure 4. Characterization of TB40-ANCHOR3 viruses .**

Viral particles derived from the TB40-ANCHOR3 HCMV BAC contain DNA, OR3-GFP proteins and stain for pp28 tegument proteins (a) and for gB envelope proteins (b) and therefore likely correspond to mature viruses, possibly with OR proteins bound to the encapsidated genomes. Images acquired with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 63X






**Fig.5****a****b****c**

**Figure 5. OR-FP specifically bind to their target ANCH sequence generating the spots observed in fluorescence microscopy.** a)ChIP experiment showing that Chromatin extracted from TB40-ANCHOR3 HCMV infected MRC5 cells (but not from TB40-GFP Infected cells) and immunoprecipitated with anti-GFP antibody is only enriched in ANCH3 and GFP sequences; hatched section corresponds to background noise, since no ANCH3 sequence is present in the TB40-GFP virus; b) MRC5 cells were transfected with a single vector expressing OR2-GFP and then infected or not with TB40-ANCH2-Kana viruses; spots appear only when OR-FP and the corresponding ANCH target sequences on the viral genomes are present simultaneously in the same cell. Images acquired 24 h post transfection and 72h post infection with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 63X or a Zeiss LSM 510 NLO; c) MRC5 cells were transfected with an expression vector for OR3-mCherry or infected with TB40-GFP or transfected and infected simultaneously; no spot are observed in any situation indicating that nor OR3 proteins neither TB40-GFP genomes form unspecific spots, even when present simultaneously in the same cell.




**Fig.6**



**Figure 6. Visualization of ANCHOR -HCMV infection steps in living cells.**

MRC5 cells were infected with TB40-ANCHOR3 HCMV viruses at an MOI of 0.5; a) about 16-17 hours pi, some very faint spots appear in infected cells which possibly correspond to incoming viral genomes (white arrows, 63X); b) distinct areas suggestive of pre-replicative sites develop around the initial spots which multiply while these areas increase in size (white arrows, 63X); c) later in infection (around 70-80h pi.), these areas fuse in a unique putative replication compartment (RC) which continues to grow (40X, scale bar 10 $\mu$ m); d) an infected MRC5 cell imaged 72h pi.: the nucleus contains a large replication compartment (RC) with numerous brilliant spots (red triangles) while fainter spots are visible in the nucleus outside the RC (black triangles) and in the cytoplasm (white triangles)(63X). All images acquired with a wide-field Zeiss Axiovert, Observer Z1, 1.4NA objective 40X or 63X.

**Fig 7**



**Figure 7. The putative replication and assembly compartments.**


TB40-ANCHOR3 HCMV infected MRC5 cells were stained for pUL44 at different times pi. a) 24h pi. b) At 72h pi., only the putative RC is positive for pUL44 confirming its status. For each time point, upper left: Hoechst 33342, upper right: OR-GFP fluorescence, lower left: anti-pUL44, lower right: merge.

TB40-ANCHOR3 HCMV infected MRC5 cells were stained for the pp28 tegument protein at different times pi. (c and d) or for the envelope gB protein (e). c) 24h pi., pp28 is already expressed but appears diffuse in the whole cell. d) On the contrary, 72h pi., pp28 is concentrated in a large region close to the nucleus where OR-GFP spots are also visible suggesting this region is the Assembly Compartment. For each time point, upper left: Hoechst 33342, upper right: OR-GFP fluorescence, lower left: anti-pp28, lower right: merge. e) TB40-ANCHOR3 HCMV infected MRC5 cells were stained for the gB envelope protein 72h pi. showing accumulation in a region close to the nucleus, especially in the central area of this region; upper left: Hoechst 33342, upper right: OR-GFP fluorescence, lower left: anti-gB, lower right: merge.




**Fig. 8**


**a**




**b**



**c**






**Figure 8. Visualization of infected cell by correlative fluorescence-electron microscopy.**

a) Cells infected with TB40-ANCHOR3 HCMV were first analyzed by fluorescence microscopy 96h pi. and then fixed and processed for electron microscopy examination (scale bar 2 $\mu$ m). The zone delimited by a yellow square has been further analyzed with higher magnification in d); b) in the RC, electron microscopy reveals different forms of capsids, possibly the type A, B and C capsids shown by black, red and white arrows respectively (scale bar 200nm); c) at higher magnification, other, possibly more diverse, forms of capsids seem to appear, with some containing dense fragmented material (white arrows) d) in the chosen area (corresponding to yellow box in a), 4 capsids are observed by EM, which all correspond to fluorescent spots. Three appear as B forms (white arrows) and one as a A form (red arrow). Spots associated with the three type B capsids present similarly weak intensities suggesting they contain a single viral genome. On the contrary, the type A capsid coincides with a much brighter spot and could be associated to a replicating structure with several genomes (scale bar 500nm). Pink color is an artefact resulting from the merging procedure.







**Fig. 9**



**Figure 9. ANCHOR technology allows quantification of HCMV infection in live cells.**

a) Fluorescent spots in an MRC5 cell infected with TB40-ANCHOR3 HCMV 72h pi.; as demonstrated above, each spot corresponds to one or several fused genomes; b) same image as a) but treated to filter out the fluorescence background and then processed using spot detector plugin for ImageJ (spot radius 2, cutoff 0, percentile 7) allowing detection of 1155 ANCHOR foci: 1005 particles in the RC, 16 nuclear particles outside of RC and 134 cytoplasmic particles; c) images were then converted into 3D intensity surface plot (perspective) or, d) into a picture in X,Z to assess particles intensity. A single viral genome corresponds to 30 arbitrary fluorescence units (FU). In the RC, all spots harbor between 2 and 5 viral genomes and this number decreases from the center to the periphery, suggesting a highly organized territory. Outside the RC, only unique genomes are observed (see text for explanations).

**Fig. 10**



**Figure 10. Cell type specific effect of Ganciclovir on TB40-ANCHOR3 HCMV infection and IC50 determination by automated high content imaging.**

a) TB40-ANCHOR3 HCMV infected cells were treated or not with 12.5 $\mu$ M Ganciclovir. 72 hours pi, cells were observed using a Thermo Scientific Cellomics Arrayscan Vti microscope and images analyzed with the compartmental analysis algorithm allowing detection of viral DNA (in red, see Material and Methods for explanation); b) similar experiment as a) but TB40-ANCHOR3 HCMV infected cells were treated with increasing doses of Ganciclovir. Results of the quantification were plotted against Ganciclovir concentrations (see text) allowing precise determination of IC50 and IC90. Two identical experiments were performed on separate plates (A and B); c) time course of TB40-ANCHOR3 HCMV infections in MRC5 or ARPE-19 cells, in the presence or not of 2.5 $\mu$ M Ganciclovir. In MRC5 cells, infection progresses to reach more than 70% infected cells 10 days pi and this infection is partly controlled by Ganciclovir. ARPE-19 cells do not seem to be highly permissive and 2 to 3% of the cells only become infected, in the presence or not of Ganciclovir; d) same experiment as in c) but using viral DNA quantification as a read-out.



**Table 1**

<b>Measured virus titer</b>				
	<b>Plaque-forming assay</b>		<b>Fluorescence</b>	
<i>μL stock virus</i>	<i>2h infection</i>	<i>18h infection</i>	<i>2h infection</i>	<i>18h infection</i>
10 <sup>-4</sup>	6,0 10 <sup>7</sup>	2,0 10 <sup>8</sup>		
10 <sup>-3</sup>	5,2 10 <sup>7</sup>	1,6 10 <sup>8</sup>	2,1 10 <sup>7</sup>	1,2 10 <sup>8</sup>
10 <sup>-2</sup>	2,8 10 <sup>7</sup>		3,9 10 <sup>7</sup>	4,2 10 <sup>8</sup>
10 <sup>-1</sup>			1,2 10 <sup>8</sup>	1,9 10 <sup>8</sup>

**Table 1. Measure of the TB40-ANCHOR3 HCMV stock virus titer.**

Titer was measured using a classical plaque forming assay and a fluorescence assay. See Material and Methods for details. Whatever the technique, measured titers are significantly higher when infection time is increased from 2h to 18 h. However, very similar results are obtained with both techniques.

Table 2						
Day pi.	TB40-GFP			TB40-ANCHOR3		
	Cells/well( $\times 10^{-3}$ )	Infected cells/well( $\times 10^{-3}$ )	Viral genomes /infected cell( $\times 10^{-3}$ )	Cells/well( $\times 10^{-3}$ )	Infected cells/well( $\times 10^{-3}$ )	Viral genomes /infected cell( $\times 10^{-3}$ )
2	129/132	9.1/9	0.17/0.13	111/114	9.6/13.9	9.4/8.3
4	316/295	26.7/40.6	0.21/0.44	254/288	27.3/33.2	10.7/16.5
6	282/289	76.4/78.8	0.71/0.83	226/256	50.5/36.8	14.3/19.2
8	232/240	79.4/79.3	1.3/1.4	135/210	66.1/44.5	9.4/12.7
10	234	89.6	0.54	167	89.1	2.3

**Table 2. Replication kinetics of TB40-GFP and TB40-ANCHOR3 viruses.**

MRC5 cells were infected at an MOI of 0.2. Cells and supernatants were harvested on days 2, 4, 6, 8 and 10 post-infection and DNA purified from each sample. Total numbers of viral genomes were determined for each sample using qPCR. Cells and infected cells were counted in a parallel plate. Each measure was made in triplicate and mean values of the two wells per time point are given for each day (except for day 10 pi.).